Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allos Therapeutics, Inc.
Allos Therapeutics Announces Updated Data from Pivotol Phase 2 PROPEL Study of Pralatrexate to be Presented at ASCO 2009
June 2nd, 2009
Allos Therapeutics, Inc. (Nasdaq: ALTH) announced that updated data from its pivotal Phase 2 PROPEL study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma will be presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held in Orlando, Fla., from May 29 to June 2, 2009. The final results from the PROPEL study were reported in early February and formed the basis of the Company’s New Drug Application (NDA), which was submitted to the U.S. Food and Drug Administration (FDA) in March 2009. The poster presentation at ASCO will include analyses of response rate and durability of response, as well as...
Source: Cancer Weekly (2009-06-02)
|
